{"id":934482,"date":"2026-02-05T08:51:41","date_gmt":"2026-02-05T13:51:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/"},"modified":"2026-02-05T08:51:41","modified_gmt":"2026-02-05T13:51:41","slug":"biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/","title":{"rendered":"BioCryst to Report Fourth Quarter 2025 Financial Results on February 26"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\"> RESEARCH TRIANGLE PARK, N.C., Feb.  05, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-aqtyM1YePG_TP-khoMAsdkl3ky0878JlNbm6eMmV_6UAw2ps56uynK1SLiPonhPuNZaC0Xb5--yPntlpsDLwVQezZKZ-1c82OX4JfZ2atoQI181sFEhy-wW-jh9Qp9j\" rel=\"nofollow\" target=\"_blank\">BioCryst Pharmaceuticals, Inc.<\/a> (Nasdaq:\u00a0BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday, February 26, 2026.<\/p>\n<p align=\"justify\">BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.<\/p>\n<p align=\"justify\">The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gaUVWPDdpnX1PQwJ1JaBIcdXIFMS2l9qP7g-LpdSoMC1jazMFYtFu5_dUxPDinTKUB3HpLMIEhWWRpgpBIFysEdpIKg8RHEBhcfesOp7bSs=\" rel=\"nofollow\" target=\"_blank\">www.biocryst.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BioCryst Pharmaceuticals <\/strong><br \/>\n        <br \/>BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (\u201cHAE\u201d) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO<em>\u00ae<\/em> (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gaUVWPDdpnX1PQwJ1JaBIVJ64qbz5mRjTEt2sP0qnj05tRrEARfq_bm4KkVXdVQUCLOTHiU9QBrJi8zWJ7NY0v5DTOZh74LSagkdE449bGE=\" rel=\"nofollow\" target=\"_blank\">www.biocryst.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3U573p9CE_0Xj-Q8PYTubwHFb254oACJ3Dj0COUKdyyOOCxKiMkbEsaN1qbeKx3-NBZwDvvm73P4xmdzNN4imUuszp5jri0IAILKepMBthxpZhhP5gNh2hm2W-Jbombu\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">BCRXW<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Contact:<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>investorrelations@biocryst.com<\/p>\n<p align=\"justify\">\n        <strong>Media:<\/strong><br \/>\n        <br \/>media@biocryst.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODk0MCM3NDA5NTE2IzIwMDQ3MTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjM2Y2NiODYtYWFkZi00ZGI5LWJjZDctMmQ0MDE5MjlhNDBjLTEwMTYyODctMjAyNi0wMi0wNS1lbg==\/tiny\/BioCryst-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) &#8212; BioCryst Pharmaceuticals, Inc. (Nasdaq:\u00a0BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday, February 26, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (\u201cHAE\u201d) and other rare diseases, driven &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioCryst to Report Fourth Quarter 2025 Financial Results on February 26&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-934482","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) &#8212; BioCryst Pharmaceuticals, Inc. (Nasdaq:\u00a0BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday, February 26, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (\u201cHAE\u201d) and other rare diseases, driven &hellip; Continue reading &quot;BioCryst to Report Fourth Quarter 2025 Financial Results on February 26&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-05T13:51:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODk0MCM3NDA5NTE2IzIwMDQ3MTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioCryst to Report Fourth Quarter 2025 Financial Results on February 26\",\"datePublished\":\"2026-02-05T13:51:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/\"},\"wordCount\":203,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODk0MCM3NDA5NTE2IzIwMDQ3MTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/\",\"name\":\"BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODk0MCM3NDA5NTE2IzIwMDQ3MTQ=\",\"datePublished\":\"2026-02-05T13:51:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODk0MCM3NDA5NTE2IzIwMDQ3MTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODk0MCM3NDA5NTE2IzIwMDQ3MTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioCryst to Report Fourth Quarter 2025 Financial Results on February 26\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/","og_locale":"en_US","og_type":"article","og_title":"BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) &#8212; BioCryst Pharmaceuticals, Inc. (Nasdaq:\u00a0BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday, February 26, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (\u201cHAE\u201d) and other rare diseases, driven &hellip; Continue reading \"BioCryst to Report Fourth Quarter 2025 Financial Results on February 26\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-05T13:51:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODk0MCM3NDA5NTE2IzIwMDQ3MTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioCryst to Report Fourth Quarter 2025 Financial Results on February 26","datePublished":"2026-02-05T13:51:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/"},"wordCount":203,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODk0MCM3NDA5NTE2IzIwMDQ3MTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/","name":"BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODk0MCM3NDA5NTE2IzIwMDQ3MTQ=","datePublished":"2026-02-05T13:51:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODk0MCM3NDA5NTE2IzIwMDQ3MTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODk0MCM3NDA5NTE2IzIwMDQ3MTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-fourth-quarter-2025-financial-results-on-february-26\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioCryst to Report Fourth Quarter 2025 Financial Results on February 26"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=934482"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934482\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=934482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=934482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=934482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}